ABBV-400 + 5-FU, leucovorin, and budigalimab for gastroesophageal adenocarcinoma - Clinical Trial

or email

gi-oncology-cru@dm.duke.edu

¿Cuál es el Propósito de este estudio?

We are doing this study to see if the study drugs ABBV-400 and budigalimab, in combination with chemotherapy, are a safe and effective option for treating gastroesophageal cancer. We are also trying to find the best dose of ABBV-400 to use.

¿Cuál es la Condición que se está estudiando?

Gastroesophageal Adenocarcinoma

¿Quién puede participar en el Estudio?

Adults ages 18+ who:

Are diagnosed with gastroesophageal adenocarcinoma
Have disease that is inoperable, advanced, or metastatic
Have not received any previous treatment for their cancer

For more information, contact the study team at dana.a.warren@duke.edu.

Grupo etario

Adultos

¿Qué Implica?

Si elige unirse a este estudio, podrá:

Receive infusions of budigalimab every 4 weeks
Receive chemotherapy every 2 weeks
Hágase biopsia del tumor
Tomar muestras de sangre
Realice tomografías computarizadas o resonancias magnéticas de manera regular.

Depending on which arm of the study you are assigned to join, you may:

Receive infusions of ABBV-400 every 2 weeks; OR
Receive infusions of ABBV-400 every 4 weeks: OR
Receive no doses of ABBV-400

Detalles del Estudio

Título Completo

[M24-977] A Phase 2 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with Fluorouracil, Leucovorin, and Budigalimab as First-Line Treatment in Subjects with Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA-977)

Investigador Principal